NASDAQ: QNCX
Quince Therapeutics Inc Stock Ownership - Who owns Quince Therapeutics?

Insider buying vs selling

Have Quince Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Brendan HannahCBO COO CCO2025-06-1837,736$1.20
$45.28kBuy
Charles S. RyanPresident2025-06-187,548$1.20
$9.06kBuy
Dirk ThyeCEO and CMO2025-06-18150,944$1.20
$181.13kBuy

1 of 1

QNCX insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when QNCX insiders and whales buy or sell their stock.

QNCX Shareholders

What type of owners hold Quince Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Epiq Capital Group LLC42.36%22,753,059$37.54MInsider
David Lamond8.16%4,384,096$7.23MInsider
Pierre Lamond5.37%2,886,530$4.76MInsider
Pfizer Inc5.36%2,879,973$4.75MInsider
Takeda Ventures Inc4.99%2,679,802$4.42MInsider
Nantahala Capital Management LLC4.71%2,528,302$4.17MInstitution
Vanguard Group Inc2.71%1,454,038$2.40MInstitution
Stephen S. Dominy2.68%1,437,674$2.37MInsider
Casey Lynch2.20%1,180,580$1.95MInsider
Dirk Thye1.85%994,885$1.64MInsider

1 of 3

QNCX vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
QNCX14.11%76.73%Net Buying
ESLA1.71%80.01%
PRLD45.30%54.70%Net BuyingNet Selling
ADVM30.21%69.79%Net Buying
CBUS21.28%78.72%Net Buying

Quince Therapeutics Stock Ownership FAQ

Who owns Quince Therapeutics?

Quince Therapeutics (NASDAQ: QNCX) is owned by 14.11% institutional shareholders, 76.73% Quince Therapeutics insiders, and 9.16% retail investors. Epiq Capital Group LLC is the largest individual Quince Therapeutics shareholder, owning 22.75M shares representing 42.36% of the company. Epiq Capital Group LLC's Quince Therapeutics shares are currently valued at $37.54M.

If you're new to stock investing, here's how to buy Quince Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.